このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

スイートスポット - 非栄養甘味料が健康に及ぼす影響

2026年11月5日 更新者:Monica Mars、Wageningen University

SweetSpot - 健康成人における非栄養性甘味料が血糖調節、腸内細菌叢、および腸管ホルモン分泌に及ぼす影響:完全管理クロスオーバー介入研究

The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.

The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.

The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.

The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.

The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.

Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.

研究の種類

介入

入学 (推定)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Gelderland
      • Wageningen、Gelderland、オランダ、6708WG
        • Wageningen University & Research

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

45年~79年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age 45-79 years;
  • BMI of 20-35 kg/m2;
  • Having veins suitable for placement of a venflon catheter.

Exclusion Criteria:

  • Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
  • Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
  • Diagnosed with type 1 or type 2 diabetes;
  • Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
  • HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
  • Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
  • Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
  • Use of antibiotics over the last 3 months before study start;
  • Donated blood within 2 months prior to the screening;
  • Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
  • Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
  • Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
  • Not willing to consume non-nutritive sweeteners;
  • Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
  • Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
  • Intention to lose or gain weight;
  • Working night shifts regularly;
  • Smoking regularly
  • Use of soft and/or hard drugs (cannabis included);
  • Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
  • Being pregnant or lactating or planning to become pregnant;
  • Inability to understand study information and/or communicate with staff;
  • Participation in another study that involves an intervention within two months prior to the intervention;
  • Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
他の:NNS / no-NNS

In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

他の:No-NNS / NNS

In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
時間枠:Week 2 and week 8 in both intervention periods (4 times in total)

The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period.

Week 2 and week 8 in both intervention periods (4 times in total)

二次結果の測定

結果測定
メジャーの説明
時間枠
Matsuda index
時間枠:Week 2 and week 8 in both intervention periods (4 times in total)

Matsuda index after an OGTT

Week 2 and week 8 in both intervention periods (4 times in total)
Fasting blood glucose
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood glucose

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Fasting blood insulin
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood insulin

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial insulin response
時間枠:Week 2 and 8 in both intervention periods (4 times in total).

2-hour iAUC blood insulin during OGTT

Week 2 and 8 in both intervention periods (4 times in total).
Postprandial glucose response after a breakfast
時間枠:Week 7 in both study periods (2 times in total)

Postprandial blood glucose responses (PPGR) following specific meals measured by CGM.

Week 7 in both study periods (2 times in total)
Blood lipid profile
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Gut microbiota composition
時間枠:Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota composition in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Gut microbiota function
時間枠:Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota functionality measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Microbial metabolites
時間枠:Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbial metabolites measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Small intestinal microbiota composition
時間枠:Week 7 of both intervention periods (2 times in total).

Microbiota composition of the small intestine measured with Simba Capsules

Week 7 of both intervention periods (2 times in total).
Gastro-intestinal transit time
時間枠:Baseline & week 7 of both intervention periods (3 times in total).

Gastro-intestinal transit time measured with blue muffins.

Baseline & week 7 of both intervention periods (3 times in total).
Oral microbiome composition & function
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Oral microbiome composition & function measured in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial GLP-1 secretion
時間枠:Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GLP-1 during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Postprandial GIP secretion
時間枠:Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GIP during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Sweetness-liker phenotype
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness-liker phenotype, with the sweetness liker test.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweetness preference & liking
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweet taste sensitivity
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Excretion of NNS in urine
時間枠:Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).

Excretion of NNS in urine

Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
Excretion of NNS in saliva
時間枠:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Excretion of NNS in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

その他の成果指標

結果測定
メジャーの説明
時間枠
Anthropometrics
時間枠:Baseline

Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2.

Baseline
Body composition
時間枠:Baseline & week 8 of both intervention periods (3 times in total).

Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry).

Baseline & week 8 of both intervention periods (3 times in total).
Habitual food intake
時間枠:Baseline

Habitual dietary intake assessment with a food frequency questionnaire (FFQ).

Baseline
Physical activity level
時間枠:Baseline.

Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH).

Baseline.
Habitual NNS consumption
時間枠:Baseline

Habitual NNS consumption by questionnaire

Baseline
Gastro-intestinal symptoms
時間枠:Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Gastro-intestinal symptoms by GSRS questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Satiety
時間枠:Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Satiety questionnaire, adapted from the Control of Eating Questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Genetic variation
時間枠:Baseline

Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat.

Baseline
Taste function
時間枠:Baseline

Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips.

Baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月23日

一次修了 (推定)

2027年3月26日

研究の完了 (推定)

2027年3月26日

試験登録日

最初に提出

2026年1月13日

QC基準を満たした最初の提出物

2026年1月13日

最初の投稿 (実際)

2026年1月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NL010297

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。